New Analyst Forecast: $MIST Given 'Hold' Rating
Milestone Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Milestone Pharmaceuticals Analyst Ratings
Express News | Milestone Pharmaceuticals Inc : H.c. Wainwright Cuts Target Price to $10 From $25
TD Cowen Downgrades Milestone Pharmaceuticals to Hold From Buy
TD Cowen Downgrades Milestone Pharmaceuticals(MIST.US) to Hold Rating
Is Milestone Pharmaceuticals (NASDAQ:MIST) Using Debt Sensibly?
SA Asks: Which Small/mid-cap Cardiology Stocks Are Undervalued?
Top Midday Decliners
Sector Update: Health Care Stocks Mixed Friday Afternoon
Trending Stocks Today | Portage Biotech Shoots up 98.51%
Sector Update: Health Care
Milestone Pharmaceuticals: Buy Rating Affirmed Despite CARDAMYST Approval Delay, Strong Market Potential and Robust Financial Position
Piper Sandler Adjusts Price Target on Milestone Pharmaceuticals to $4 From $5, Maintains Overweight Rating
Why Is Milestone Pharmaceuticals Stock Plunging Today?
Milestone Pharmaceuticals Says FDA Cites Manufacturing Concerns for Etripamil NDA; Shares Fall
Nasdaq Down 100 Points; Federal Reserve's Favorite Inflation Gauge Increases More Than Expected
12 Health Care Stocks Moving In Friday's Pre-Market Session
FDA Rejects Milestone Pharmaceuticals' Etripamil Nasal Spray
Milestone Pharma Says FDA Declined to Approve Heart Disorder Therapy